ARTICLE | Clinical News
Vismed: Phase III started
January 22, 2007 8:00 AM UTC
Lantibio began a double-blind, placebo-controlled, U.S. Phase III trial in 300 patients. The trial has an SPA from FDA. Last year, Lantibio licensed Vismed from TRB Chemedica, which markets the produc...